JACC. Case reports · 2026
Obstructive Hypertrophic Cardiomyopathy in a Symptomatic Professional Athlete Treated With Mavacamten.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bavishi Aakash, Marella Dean, Kim Jonathan H, Martinez Matthew W
Аннотация
BACKGROUND: Management of left ventricular outflow tract obstruction (LVOTO) in competitive athletes with hypertrophic cardiomyopathy (HCM) is challenging, particularly when obstruction is exercise-induced and medical therapy is poorly tolerated.
CASE SUMMARY: A 28-year-old professional athlete presented with recurrent syncope. Resting imaging showed asymmetric septal hypertrophy without obstruction, but stress echocardiography revealed severe dynamic LVOTO (peak gradient: 150 mm Hg). Beta-blockers caused fatigue with persistent gradients. After shared decision-making, mavacamten was initiated. Follow-up stress imaging demonstrated complete resolution of LVOTO with preserved systolic function. The athlete returned to professional competition and remained event-free at 2 years.
DISCUSSION: Current guidelines emphasize shared decision-making for athletes with HCM. This case highlights the importance of stress imaging to unmask LVOTO and supports mavacamten as a viable alternative.
TAKE-HOME MESSAGES: Stress testing is critical in symptomatic athletes with HCM. Mavacamten may permit alleviation of LVOTO and safe return to play.
CASE SUMMARY: A 28-year-old professional athlete presented with recurrent syncope. Resting imaging showed asymmetric septal hypertrophy without obstruction, but stress echocardiography revealed severe dynamic LVOTO (peak gradient: 150 mm Hg). Beta-blockers caused fatigue with persistent gradients. After shared decision-making, mavacamten was initiated. Follow-up stress imaging demonstrated complete resolution of LVOTO with preserved systolic function. The athlete returned to professional competition and remained event-free at 2 years.
DISCUSSION: Current guidelines emphasize shared decision-making for athletes with HCM. This case highlights the importance of stress imaging to unmask LVOTO and supports mavacamten as a viable alternative.
TAKE-HOME MESSAGES: Stress testing is critical in symptomatic athletes with HCM. Mavacamten may permit alleviation of LVOTO and safe return to play.